Eli Lilly's forforglipron Shows Promising Results in Weight Loss and Obesity Treatment
TL;DR Summary
Eli Lilly's experimental oral GLP-1 pill, orforglipron, helped overweight adults with type 2 diabetes lose an average of 10.5% of their body weight in a late-stage trial, with significant improvements in blood sugar levels, positioning it as a promising alternative to injectable obesity drugs and potentially paving the way for regulatory approval and market launch next year.
- Lilly pill cuts body weight by 10.5% in patients with type 2 diabetes Reuters
- Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval CNBC
- Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Eli Lilly and Company
- Eli Lilly GLP-1 pill shows promising weight loss in type 2 diabetes trial USA Today
- Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals The Wall Street Journal
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
92%
682 → 57 words
Want the full story? Read the original article
Read on Reuters